{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:41:55Z","timestamp":1793835715368,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["LY2189265"],"award-info":[{"award-number":["LY2189265"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ekir.2026.103789","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:18:53Z","timestamp":1769041133000},"page":"103789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dulaglutide Effect on Proteins Associated With CKD Progression"],"prefix":"10.1016","volume":"11","author":[{"given":"Brandon E.","family":"McFarlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sok Cin","family":"Tye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaipul I.","family":"Md Dom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afton","family":"Kechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej S.","family":"Krolewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Duffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.103789_bib1","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.103789_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2026.103789_bib3","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.103789_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.103789_bib5","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.103789_bib6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.103789_bib7","doi-asserted-by":"crossref","first-page":"E747","DOI":"10.1152\/ajpendo.00374.2023","article-title":"Incretin and glucagon receptor polypharmacology in chronic kidney disease","volume":"326","author":"McFarlin","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ekir.2026.103789_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ekir.2026.103789_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ekir.2026.103789_bib10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.103789_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Clinical Outcomes by Albuminuria Status with dulaglutide versus insulin glargine in Participants with Diabetes and CKD: AWARD-7 exploratory Analysis","volume":"2","author":"Tuttle","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2026.103789_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178373","article-title":"Circulating proteins linked to apoptosis processes and fast development of end-stage kidney disease in diabetes","volume":"9","author":"Ihara","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ekir.2026.103789_bib13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2215\/CJN.0000000603","article-title":"Classification of predictors of rapid development of kidney failure and short-term changes in concentration of circulating proteins","volume":"20","author":"Kobayashi","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103789_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2109","article-title":"Neuroblastoma suppressor of tumorigenicity 1 is a circulating protein associated with progression to end-stage kidney disease in diabetes","volume":"14","author":"Kobayashi","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2026.103789_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.kint.2022.04.022","article-title":"Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes","volume":"102","author":"Kobayashi","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103789_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd2699","article-title":"Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes","volume":"13","author":"Md Dom","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2026.103789_bib17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2026.103789_bib18","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1681\/ASN.2021010105","article-title":"Comprehensive search for novel circulating miRNAs and axon guidance pathway proteins associated with risk of ESKD in diabetes","volume":"32","author":"Satake","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103789_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.0000000863","article-title":"Joslin kidney panel of circulating proteins: a tool for ESKD risk discrimination and individualized diabetic kidney disease treatment","volume":"21","author":"Krolewski","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103789_bib20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103789_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like Peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.103789_bib22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cmet.2021.04.004","article-title":"KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease","volume":"33","author":"Mori","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2026.103789_bib23","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.ekir.2022.03.033","article-title":"Biomarkers of kidney tubule disease and risk of end-stage kidney disease in persons with diabetes and CKD","volume":"7","author":"Amatruda","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.103789_bib24","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1681\/ASN.2016101101","article-title":"Plasma biomarkers and kidney function decline in early and established diabetic kidney disease","volume":"28","author":"Coca","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103789_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1681\/ASN.2020040487","article-title":"Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the chronic renal insufficiency cohort (CRIC) study","volume":"32","author":"Schrauben","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103789_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2215\/CJN.03010608","article-title":"Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes","volume":"4","author":"Niewczas","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103789_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1043-2760(00)00272-1","article-title":"Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes","volume":"11","author":"Moller","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ekir.2026.103789_bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.orcp.2019.03.003","article-title":"Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-alpha-mediated NF-kappaB and MAPK pathway","volume":"13","author":"Ye","year":"2019","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.ekir.2026.103789_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Noyan-Ashraf","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.103789_bib30","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","article-title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","volume":"34","author":"Wong","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2026.103789_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000529374","article-title":"Indicators of kidney fibrosis in patients with type 2 diabetes and chronic kidney disease treated with dulaglutide","volume":"54","author":"Tuttle","year":"2023","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.103789_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bbrc.2015.09.121","article-title":"Roles of layilin in TNF-alpha-induced epithelial-mesenchymal transformation of renal tubular epithelial cells","volume":"467","author":"Adachi","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ekir.2026.103789_bib33","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1253\/circj.CJ-14-1195","article-title":"Syndecan-1 in acute decompensated heart failure--association with renal function and mortality","volume":"79","author":"Neves","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.ekir.2026.103789_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/CIRCULATIONAHA.106.644609","article-title":"Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction","volume":"115","author":"Vanhoutte","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.103789_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:23:08Z","timestamp":1775265788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2468024926000203"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.103789","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dulaglutide Effect on Proteins Associated With CKD Progression","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.103789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103789"}}